|
|
|
|
European Biopharmaceutical Review |
| |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique
position in scientific publishing. Published quarterly, it provides a dedicated platform
of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.
With editorial consisting of in-depth articles, case studies, meetings, and report
reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical
research and development, with regular feature sections on BioBusiness
Development, Research and Innovation, BioDiscovery, BioManufacturing
plus special focusses on geographic or therapeutic territories.
Connect with us on Twitter: follow @EBRmagazine
Read
our publications on the go in the Samedan app for phones and tablets. You
can download issues for offline reading, and our archives go as far back
as 2008! Download for free on the App Store, GooglePlay, or Amazon.   
|
|
|
|
|
|
Widgets Magazine
 |
Industry Events |
 |
2020 Avoca Quality and Innovation Summit
3-4 June 2020, Amsterdam, The Netherlands
The 2020 Avoca Quality and Innovation Summit will take place 3-4 June
2020, in Amsterdam, The Netherlands.
More info >> |
|
 |
News and Press Releases |
 |
High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals
Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >> |
|
 |
White Papers |
 |
|
Running Better Trials Taking an Intelligent Monitoring Approach
Bioclinica
When it comes to implementing a risk-based monitoring program, it is not
just about reducing monitoring visits and doing less Source Document
Verification (SDV). It’s about bringing together your people, a solid
process, and the right technology to run a better trial.
Success
with risk-based monitoring requires the ability to make sense of the
thousands, if not millions, of data points captured by multiple
disparate sources in a clinical trial. With the sheer volume of data
generated on a daily basis comes complexity. How does one make sense of
it all? Information overload burdens even the most experienced study
teams who struggle to understand which data matters most and what it
means.
More info >> |
|
|
